Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Dr. Reddy's Laboratories Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Dr. Reddy's Laboratories hat ein Gesamteigenkapital von ₹280.6B und eine Gesamtverschuldung von ₹14.0B, wodurch sich der Verschuldungsgrad auf 5% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹387.5B bzw. ₹107.0B. Dr. Reddy's Laboratories Das EBIT des Unternehmens beträgt ₹66.2B, so dass der Zinsdeckungsgrad -16.6 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹81.5B.

Wichtige Informationen

5.0%

Verhältnis von Schulden zu Eigenkapital

₹14.03b

Verschuldung

Zinsdeckungsgrad	-16.6x
Bargeld	₹81.47b
Eigenkapital	₹280.55b
Gesamtverbindlichkeiten	₹106.97b
Gesamtvermögen	₹387.52b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well

Jan 10

Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?

Sep 28

Recent updates

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00

May 26

Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00

May 10

With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case

May 06

There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding

Apr 18

Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 02

Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?

Jan 19

Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E

Jan 01

Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet

Oct 21

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Oct 03

Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt

Jul 14

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00

Jun 24

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year

Jun 10

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00

May 27

Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00

May 13

Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?

Apr 11

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Mar 06

These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well

Jan 10

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Dec 05

Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?

Sep 28

Do Dr. Reddy's Laboratories' (NSE:DRREDDY) Earnings Warrant Your Attention?

Aug 17

Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Shares Could Be 33% Above Their Intrinsic Value Estimate

Jul 21

Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹30.00

Jul 08

Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Larger Dividend Than Last Year At ₹30.00

Jun 22

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: DRREDDYDie kurzfristigen Aktiva des Unternehmens (₹248.0B) übersteigen seine kurzfristigen Passiva (₹96.0B).

Langfristige Verbindlichkeiten: DRREDDYDie kurzfristigen Vermögenswerte des Unternehmens (₹248.0B) übersteigen seine langfristigen Verbindlichkeiten (₹10.9B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: DRREDDY über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: DRREDDY Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 26.9% auf 5% zurückgegangen.

Schuldendeckung: DRREDDYDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (323.8%).

Zinsdeckung: DRREDDY mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

Dr. Reddy's Laboratories Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet

Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt

Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?

These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well

Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?

Recent updates

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00

Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00

Dividend of ₹40.00 announced

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case

Dr. Reddy's Laboratories Limited Announces Executive Changes

There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet

High number of new directors

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Price target increased by 7.7% to ₹5,388

Dr. Reddy's Laboratories Limited Announces Management Changes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Upcoming dividend of ₹40.00 per share at 0.8% yield

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00

Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?

Do Dr. Reddy's Laboratories' (NSE:DRREDDY) Earnings Warrant Your Attention?